Bartronics India Limited (BIL) has announced a strategic investment of up to ₹50 crore in Huwel Life Sciences Pvt. Ltd, a Hyderabad-based molecular diagnostics innovator. This move marks a significant step towards advancing affordable diagnostics in India and global health markets.

Key Highlights of the Partnership

• BIL will acquire a 15% equity stake in Huwel Life Sciences, with an option to increase it by an additional 15%.
• The collaboration aims to combine BIL's scaling expertise with Huwel's innovation capabilities.
• Huwel Life Sciences, led by Dr. Rachana Tripathi, has developed over 100 validated diagnostic products across various diseases.
• The partnership focuses on expanding market reach, technology support, and securing government and international orders.

Huwel Life Sciences: A Leader in Diagnostic Innovation

Huwel Life Sciences, operating from an ISO-certified, CE/FDA-compliant facility in Hyderabad, has made significant strides in the field of diagnostics:

• Developed more than 100 validated diagnostic products for TB, infectious diseases, cancer, and more.
• Played a crucial role during the COVID-19 pandemic by delivering RT-PCR solutions at scale.
• Secured grants from the Bill & Melinda Gates Foundation and received orders from the World Health Organization.

Flagship Product: Quantiplus® TB Fast Detection Kit

The partnership's cornerstone is Huwel's breakthrough low-cost TB solution:

• Quantiplus® TB Fast Detection Kit is approved by ICMR and launched by the Union Health Minister.
• It's the only open-system, affordable RT-PCR solution for TB confirmatory testing in India.
• Aligns with the National TB Elimination Programme (NTEP) and the vision of a 'TB Mukt Bharat'.

Bartronics India's Role and Benefits

Under this strategic partnership, Bartronics India will:

• Drive market growth and deliver technology support.
• Manage digital outreach and develop customized applications and platforms.
• Lead in identifying opportunities, negotiating commercial terms, and securing orders.
• Benefit from assured revenue through a designated subsidiary managing business execution.

Future Outlook

Mr. Vidhya Sagar Reddy, Managing Director of Bartronics India Limited, emphasized the partnership's potential: "It is about building a monopoly-strength product portfolio from India for the world. It also strengthens our role in national health programs while creating recurring revenue opportunities."

Dr. Rachana Tripathi, CEO of Huwel Life Sciences, added: "With our ICMR-certified TB solution and expanding product portfolio—and with BIL's partnership, we are ready to scale across India and globally."

The collaboration between Bartronics India and Huwel Life Sciences aims to:

• Strengthen India's healthcare system
• Accelerate disease elimination programs
• Establish global leadership in affordable diagnostics
• Expand into emerging markets in Africa and Southeast Asia

This partnership represents a significant step towards positioning India as a global hub for life sciences innovation and manufacturing, promising a healthier future for India and the world.

Bartronics India Limited (BIL) has announced a series of strategic moves aimed at fostering growth and innovation. The company's Board of Directors has approved several key decisions that could significantly impact its future trajectory.

Strategic Investment in Huwel Life Sciences

BIL's board has given the green light to a Memorandum of Understanding (MoU) with Huwel Life Sciences Private Limited. This agreement outlines a strategic equity investment of up to ₹50.00 crore, to be made in tranches. Upon completion of this investment, Bartronics is set to acquire up to 15% stake in Huwel's fully diluted equity share capital.

The proposed investment is subject to several conditions, including:

• Detailed due diligence
• Execution of definitive agreements
• Receipt of necessary statutory, regulatory, and corporate approvals

This collaboration aims to support future growth, foster innovation, and explore collaborative business opportunities between the two companies.

Proposal for Company Name Change

The Board of Directors has approved a proposal to initiate steps for changing the company's name. This decision is subject to shareholder approval and other necessary statutory authorizations. The specifics of the new name have not been disclosed.

Incorporation of Wholly Owned Subsidiary

BIL's board has approved the incorporation of a wholly owned subsidiary in India. This new entity is expected to enhance operational efficiency and enable the company to pursue new business opportunities, supporting its long-term growth strategy.

Board Meeting Details

The decisions were made during a board meeting held on September 23. The meeting commenced at 3:20 p.m. (IST) and concluded at 4:05 p.m. (IST), as per the company's filing with the stock exchanges.

These strategic moves by Bartronics India Limited reflect the company's proactive approach to growth and adaptation in a dynamic business environment. The investment in Huwel Life Sciences could open up new avenues in the life sciences sector, potentially diversifying BIL's portfolio and revenue streams.